ArticleBioMed research international2014
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Exploring Influencing Factors Including CYP2C19 Genotypes, and Developing a Machine Learning-Based Predictive Model for Clopidogrel Resistance in Chinese Patients with Ischemic Stroke.International journal of general medicine · 2026Article
- GPD2 inhibition impairs coagulation function via ROS/NF-κB/P2Y12 pathway.Cellular & molecular biology letters · 2025Article
- Research advances in the etiology of in-stent restenosis of coronary arteries.Frontiers in cardiovascular medicine · 2025Review
- Influence of Genetic and Epigenetic Factors of P2YCardiovascular drugs and therapy · 2024Review
- A review on regulation of DNA methylation during post-myocardial infarction.Frontiers in pharmacology · 2024Review
- Article
- DNA methylation profile in the whole blood of acute coronary syndrome patients with aspirin resistance.Journal of clinical laboratory analysis · 2023Article
- The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.Journal of clinical laboratory analysis · 2022Article
- The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2022Article
- Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives.AJNR. American journal of neuroradiology · 2021Review
- A dry immersion model of microgravity modulates platelet phenotype, miRNA signature, and circulating plasma protein biomarker profile.Scientific reports · 2021Article
- Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).Pharmacology research & perspectives · 2021Observational
- Periprocedural Variability of Platelet Functions in Carotid Artery Stenting: An Analysis Using VerifyNow.Journal of neuroendovascular therapy · 2021Article
- Combined Therapy with Traditional Chinese Medicine and Antiplatelet Drugs for Ischemic Heart Disease: Mechanism, Efficacy, and Safety.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients.Journal of clinical laboratory analysis · 2020Article
- The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.International journal of molecular sciences · 2020Review
- Clopidogrel Resistance Is Associated With DNA Methylation of Genes From Whole Blood of Humans.Frontiers in genetics · 2020Article
- Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease.Journal of clinical laboratory analysis · 2019Article
- Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.Journal of personalized medicine · 2018Review
- Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.International journal of environmental research and public health · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClopidogrel inhibits the ADP receptor P2Y12 to keep down the platelet aggregation. The goal of our study is to investigate the contribution of P2Y12 promoter DNA methylation to the risk of clopidogrel resistance (CR).
methodsThe platelet functions were measured by the VerifyNow P2Y12 assay. Applying the bisulfite pyrosequencing technology, DNA methylation levels of two CpG dinucleotides on P2Y12 promoter were tested among 49 CR cases and 57 non-CR controls. We also investigated the association among P2Y12 DNA methylation, various biochemical characteristics, and CR.
resultLower methylation of two CpGs indicated the poorer clopidogrel response (CpG1, P=0.009; CpG2, P=0.022) in alcohol abusing status. Meanwhile CpG1 methylation was inversely correlated with CR in smoking patients (P=0.026) and in subgroup of Albumin<35 (P=0.002). We observed that the level of DNA methylation might be affected by some clinical markers, such as TBIL, LEVF, Albumin, AST. The results also showed that the quantity of stent, fasting blood-glucose, and lower HbAC1 were the predictors of CR.
conclusionsThe evidence from our study indicates that P2Y12 methylation may bring new hints to elaborate the pathogenesis of CR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.